Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Universitat de les Illes Balears
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Over 18 years of age
Female gender
ECOG score 0-2
Positive biopsy for invasive non-lobular breast tumor histology
Tumor \< 3 cm in diameter as measured by MRI or contrast mammography
Tumor located ≥ 0.5 cm from the skin or rib cage, clinically or radiologically
Positive estrogen and/or progesterone receptors
HER2 negative
No lymphovascular invasion in the biopsy
Tumor must be clinically and radiologically N0 (no lymph node involvement). If a suspicious lymph node is seen, it must be biopsied and show a negative result
Patient weight below 220 kg (weight limit for the treatment table)
Ability to tolerate the supine position for 20 minutes during treatment
Able to undergo MRI and/or contrast mammography
Not pregnant; women of childbearing potential will undergo a pregnancy test to rule this out
Contraindication to or refusal of surgical treatment, which must be explicitly documented in the medical record.
You may not be if
Under 18 years of age
Male gender
ECOG score 3-4
Positive biopsy for invasive lobular carcinoma or ductal carcinoma in situ
Tumor ≥ 3 cm in diameter as measured by MRI
Tumor located \< 0.5 cm from the skin or rib cage, clinically or radiologically
Negative estrogen and progesterone receptors
HER2 positive
Presence of lymphovascular invasion in the biopsy
Positive BRCA mutation
Multicentric tumor
Tumor with positive axillary lymph nodes
Patients with metastatic disease
History of previous breast cancer in the same breast
Previous thoracic radiotherapy
Pregnant or actively breastfeeding
Unable to undergo MRI or contrast mammography
Unable to tolerate the supine position
Patient with breast implants
Patients with pacemakers
Scleroderma, lupus, or other connective tissue diseases with active flares
Inability to understand and sign the informed consent
Clareo Health | A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial
